Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011

Ian Morrissey*, Harald Seifert, Rafael Canton, Patrice Nordmann, Stefania Stefani, Alasdair MacGowan, Regina Janes, Daniel Knight, R. Bonnet, C. J. Soussy, R. Courcol, R. Leclercq, R. Zahar, C. Poyart, Y. Rio, W. Pfister, C. Schoerner, F. Albert, E. Jacobs, S. SchubertR. Mutters, F. J. Schmitz, F. Luzzaro, E. Manso, C. Scarparo, G. Fadda, F. Rossano, G. M. Rossolini, G. P. Gesu, M. P. Landini, L. Martínez, J. L. Pérez, C. Gimeno, Á Pascual, J. Liñares, R. Bartolomé, R. Cisterna, K. Gould, Matthew Dryden, M. Weinbren, A. Swann, M. Wilcox, G. Moore, J. Andrews, J. Ashby, S. Kaul

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)

Abstract

Objectives: To determine the activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci (VRE) and β-haemolytic streptococci recently isolated from acute bacterial skin and skin structure infections or bacteraemia in western Europe. Methods: Forty-one centres in Spain (8), Italy (9), Germany (8), France (8) and the UK (8) submitted 866 isolates [204 methicillin-resistant Staphylococcus aureus (MRSA), 177 methicillin-resistant coagulase-negative staphylococci (MRCoNS), 101 VRE, 193 Streptococcus agalactiae and 191 Streptococcus pyogenes] that were collected during the first 6 months of 2011. These were re-identified and susceptibilities to oritavancin and comparators were determined. Results: Oritavancin was very active against MRSA (MIC50/MIC90 0.03/0.06 mg/L), MRCoNS (0.06/0.12 mg/L), VRE (0.03/0.06 mg/L), S. agalactiae (0.03/0.06 mg/L) and S. pyogenes (0.06/0.25 mg/L). The highest oritavancin MIC observed was 0.25 mg/L (species were S. aureus, Staphylococcus epidermidis, Staphylococcus hominis, S. agalactiae, S. pyogenes and Enterococcus faecalis). Conclusions: These data from recently collected Gram-positive bacteria in western Europe confirm the potent in vitro activity of oritavancin against a wide range of resistant MRSA, MRCoNS and VRE isolates, including ones resistant to newer agents.

Original languageEnglish
Pages (from-to)164-167
Number of pages4
JournalJournal of Antimicrobial Chemotherapy
Volume68
Issue number1
DOIs
Publication statusPublished - Jan 2013

Bibliographical note

Funding Information:
I. M. is a former employee of Quotient Bioresearch Ltd, which received funding to carry out the laboratory work from The Medicines Company and has received similar funding for laboratory work and consultancy from numerous other pharmaceutical companies. I. M.’s current employer is IHMA Europe Sàrl. H. S. has received research funding from Basilea, Novartis and Pfizer, has been a consultant for Astellas, AstraZeneca, Janssen-Cilag, Novartis and Wyeth, and has served on the speakers’ bureaus of Astellas, Bayer, Gilead, Infectopharm, Janssen-Cilag, MSD, Novartis, Oxoid and Pfizer. R. C. has received research funding from Novartis and has participated in educational symposia organized by Novartis and Pfizer. S. S. has received research funding from Novartis and Pfizer, has been a consultant for Roche, Novartis and Pfizer, and has served on the speakers’ bureaus of Novartis, BD and Pfizer. P. N., A. M., R. J. and D. K.: none to declare.

Funding Information:
This work was supported by educational/research grants from The Medicines Company.

Keywords

  • Europe
  • Gram-positive bacteria
  • Lipoglycopeptides

Fingerprint

Dive into the research topics of 'Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011'. Together they form a unique fingerprint.

Cite this